Royalty Pharma PLC RPRX:NASDAQ

RT Quote | NASDAQ | USD
Last | 01/24/22 EST
39.47quote price arrow up+0.33 (+0.84%)
Volume
2,096,818
52 week range
34.86 - 53.15
Loading...
  • Open38.33
  • Day High39.52
  • Day Low37.53
  • Prev Close39.47
  • 52 Week High53.15
  • 52 Week High Date01/26/21
  • 52 Week Low34.86
  • 52 Week Low Date10/06/21

Key Stats

  • Market Cap23.965B
  • Shares Out607.17M
  • 10 Day Average Volume2.15M
  • Dividend0.76
  • Dividend Yield1.93%
  • Beta-
  • YTD % Change-0.95

KEY STATS

  • Open38.33
  • Day High39.52
  • Day Low37.53
  • Prev Close39.47
  • 52 Week High53.15
  • 52 Week High Date01/26/21
  • 52 Week Low34.86
  • 52 Week Low Date10/06/21
  • Market Cap23.965B
  • Shares Out607.17M
  • 10 Day Average Volume2.15M
  • Dividend0.76
  • Dividend Yield1.93%
  • Beta-
  • YTD % Change-0.95

RATIOS/PROFITABILITY

  • EPS (TTM)1.44
  • P/E (TTM)27.47
  • Fwd P/E (NTM)13.05
  • EBITDA (TTM)1.679B
  • ROE (TTM)15.28%
  • Revenue (TTM)2.286B
  • Gross Margin (TTM)-
  • Net Margin (TTM)67.99%
  • Debt To Equity (MRQ)122.40%

EVENTS

  • Earnings Date02/15/2022
  • Ex Div Date02/17/2022
  • Div Amount0.19
  • Split Date-
  • Split Factor-

Latest On Royalty Pharma PLC

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in commercial products and development-stage product candidates. Its portfolio investments include AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s...
Pablo Legorreta
Chairman of the Board, Chief Executive Officer
Christopher Hite
Vice Chairman of the Board, Executive Vice President
Terrance Coyne
Chief Financial Officer, Executive Vice President
George Lloyd
Executive Vice President - Investments and General Counsel
James Reddoch
Executive Vice President - Research & Investments
Address
110 East 59th Street
New York, NY
10022
United States

Top Peers

SYMBOLLASTCHG%CHG
SGEN
Seagen Inc
129.55+2.00+1.57%
HZNP
Horizon Therapeutics PLC
86.85+0.43+0.50%
BMRN
Biomarin Pharmaceutical Inc
86.22+1.57+1.85%
CTLT
Catalent Inc
103.74+1.66+1.63%
RDY
Dr Reddy's Laboratories Ltd
58.98-0.72-1.21%